Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Title
Intervention Indication Therapeutic Area Year Actions
Maribavir for cytomegalovirus infections after transplant Maribavir (SHP620; TAK-620) Cytomegalovirus (CMV) Infectious Disease 2020 View  |  Download
Maralixibat for Progressive Familial Intrahepatic Cholestasis Type 2 Maralixibat chloride (SHP625) Progressive familial intrahepatic cholestasis (PFIC) Genetic Disorders , Hepatology 2020 View  |  Download
Luspatercept for the treatment of adults with non-transfusion dependent beta-thalassaemia Luspatercept (ACE-536; Reblozyl) Beta thalassemia Genetic Disorders , Haematology 2020 View  |  Download
Lurbinectedin in addition to doxorubicin for small-cell lung cancer after prior platinum-containing therapy Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Lurbinectedin (PM01183; Zepzelca) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2020 View  |  Download
Lorlatinib for advanced ALK-positive non-small cell lung cancer – first line Lorlatinib (PF-06463922; Lorviqua) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Lonafarnib for Hutchinson-Gilford Progeria syndrome and progeroid laminopathies Lonafarnib (Sarasar; EBP994; SCH 66336; Zokinvy) Progeria Genetic Disorders 2020 View  |  Download
LN-145 for recurrent, metastatic or persistent cervical carcinoma LN-145 Cervical cancer Female Reproductive Cancer 2020 View  |  Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line Lisocabtagene maraleucel (Liso-cel; JCAR017) Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Lisocabtagene maraleucel for relapsed or refractory, aggressive B-cell non-Hodgkin Lymphoma – second line Lisocabtagene maraleucel (Liso-cel; JCAR017) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2020 View  |  Download
Liposomal cytarabine-daunorubicin for treating relapsed or refractory acute myeloid leukaemia in paediatric patients. CPX-351 (Vyxeos Liposomal) (fixed dose combination: Cytarabine; daunorubicin) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2020 View  |  Download
1 2 6 7 8 9 10 14 15
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications